Shots:
Rhythm Pharmaceuticals reported the commercial launch of IMCIVREE (setmelanotide) in Japan for pts. with acquired hypothalamic obesity (HO), following its inclusion on Japan’s National Health Insurance drug price list
IMCIVREE is the first approved therapy in Japan for acquired HO which was approved in August 2026 by Japan’s MHLW, and supported by the P-III…
